<DOC>
	<DOCNO>NCT02006732</DOCNO>
	<brief_summary>The objective study assess efficacy safety 12 week daily treatment orally inhaled tiotropium + olodaterol FDC ( deliver Respimat inhaler ) compare tiotropium placebo patient COPD .</brief_summary>
	<brief_title>Tiotropium+Olodaterol Fixed Dose Combination ( FDC ) Chronic Obstructive Pulmonary Disease ( OTEMTO 2 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Diagnosis chronic obstructive pulmonary disease Relatively stable airway obstruction post FEV1 &gt; =30 &lt; 80 % predict normal post FEV1/ FVC &lt; 70 % Male female patient , 40 year age Smoking history 10 pack year Exclusion criterion : Significant disease COPD History asthma COPD exacerbation previous 3 month Completion pulmonary rehabilitation program within previous 6 week current participation pulmonary rehabilitation program . Pregnant nursing woman Patients unable comply pulmonary medication restriction</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>